Sentences with phrase «on approval from»

Congrats on your approval from the adoption agency!

Waiting on approval from the board proceed with Energy Efficiency inspections.

The product is still contingent on approval from the U.S. Securities and Exchange Commission, the firm indicated at the time.

Undead Labs signed a Multiple year contract, multi-title agreement with Microsoft and are likely working on a zombie MMO called Class4, but was still waiting on approval from Microsoft.

I am waiting on approval from the anesthesiologist and the surgeon who will perform the cesarean section.

Graphicly, the main competitor to Comixology in digital comics, has its retina app submitted and is just waiting on approval from Apple.

Murray Goulburn's $ 9.50 cash offer meanwhile relies on approval from the Australian Competition Tribunal, which is expected to decide on the bid's eligibility by late February.

Still, its offer is conditional on approval from the Australian Competition Tribunal, which is set to make a decision by February 28.

The leading U.S. semiconductor company is waiting on approval from Chinese regulators to merge with Dutch rival NXP Semiconductors.

However, neither currently has a licence to sell marijuana, so the deal is contingent on approval from the governments, as well as from franchisees and landlords.

The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA).

Not exact matches

«That is going to cause turbo acceleration of the income, because that is 56 percent of the market in the biggest territory and that will have a massive impact on sales from 2019,» de Winkel said, adding that a U.S. approval could come early next year.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The settlement was filed on Monday in the federal court in Manhattan and won preliminary approval from U.S. District Judge Robert Sweet.

As part of the deal, which still needs approval from Congress, Saudi Arabia «expressed its intent» to spend $ 28 billion on defense technologies and programs by Lockheed Martin, which estimated the deal would support 18,000 jobs in the U.S. over 30 years — a figure that falls dramatically below Trump's estimate.

The federal and Ontario governments issued a joint press statement on Monday declaring that approval from provinces must occur by July 15th — less than a month from now.

On Monday, U.K. prime minister Theresa May won approval from Parliament to begin talks for the country's exit from the E.U. May plans to invoke what is known as Article 50 of the Treaty of Lisbon, which outlines how an E.U. member may leave the bloc — provided it gives two years» notice.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

The online showcase Before the Label gives independent designers a platform for both sales and beta testing — designers get approval to run their designs on the site, and then list them in campaigns ranging from a couple weeks to a couple months.

Audi just showed off its new 2019 A8, the first vehicle for market with Level 3 autonomy, and the automaker still needs to get approval from regulators around the world to enable the system for use on public roads.

Wesfarmers - owned Coles has received approval from the Australian Competition and Consumer Commission for its proposed acquisition of three Metcash - owned Progressive Supa IGA supermarkets, but is yet to make a decision on the fourth.

Perth - based contractor and surveyor OTOC has obtained approval for an $ 8.1 million debt facility from the Commonwealth Bank of Australia, on top of an $ 8.2 million facility it was awarded from the CBA last year.

In early January, Ant Financial, the electronics payment affiliate of China's Alibaba Group, and MoneyGram, a Texas - based money transfer company, announced that it had been forced to abandon a proposed deal after failing to win approval from the Committee on Foreign Investment in the United States (CFIUS), a congressional panel that reviews foreign purchases of American companies.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

For businesses, this is the Holy Grail and the highest stamp of approval: a word - of - mouth recommendation on Facebook, a creative meme that goes viral on Twitter, a thumbs up from a trusted Influencer.

The judges» picks then move on to the real test: a stamp of approval from consumers themselves, who were polled by the thousands by global market research company TNS on behalf of Rogers Insights.

It's an Android device that doesn't look much different from other phones on the market, but it's still pending approval from Verizon and Sprint, according to PCMag.

Qualcomm, which plans to fund the additional $ 6 billion with cash on hand and new debt, said approval from China's Ministry of Commerce is the only regulatory nod remaining for the closure of the NXP deal.

The acquisition is not conditional on getting antitrust approvals or a green light from the Committee on Foreign Investment in the United States (CFIUS), among others.

One other tidbit from the Glassdoor study: Uber co-founder Travis Kalanick, who stepped down from his post as CEO under intense pressure on Wednesday, had an above - average 77 % approval rating.

Seadrill plans to emerge from Chapter 11 bankruptcy proceedings in late June or early July, following a U.S. court's approval on...

Meanwhile, small business loan approvals at small banks, which generally have been focusing on SBA loans in recent months, dipped to 48.7 % in December — a full percentage point from the previous month.

April 18 - Bon - Ton Stores Inc won court approval on Wednesday for a bid to wind down its operations, clearing the way for one of the largest U.S. department store chains to begin selling everything from its store inventory to leases and fixtures.

April 9 - German conglomerate Bayer AG's $ 62.5 billion bid to acquire U.S. seeds company Monsanto Co has won approval from the U.S. Justice Department, after the companies said they would sell off additional assets, the Wall Street Journal reported https://on.wsj.com/2GKhEGh on Monday.

TOKYO, March 30 - Toshiba Corp said on Friday it would not be able to complete an $ 18 billion deal to sell its prized chip unit by an agreed deadline at the end of March, as it had not received anti-monopoly approval from China.

Mims, who spoke with former Google employees, reports that the first step of phasing out the 20 percent time was requiring engineers to approval from their managers to work on such independent projects.

That information — augmented by advocacy efforts from such Addyi supporters as the National Organization for Women and National Consumers League — turned the tide, and the FDA's joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee voted 18 to 6 to support approval for HSDD treatment, contingent on Sprout consenting to risk - mitigation measures like warnings and restrictions to prevent misuse.

Now, however, cases from Alabama, North Carolina, South Carolina and Texas could prompt the court to deal head on with the issue of advance approval.

Conversion of any Second Cup cafes to dispensaries will be conditional on obtaining a license from provincial regulators as well as the approval of the applicable franchisee and landlord.

Concessions to China over Scarborough would likely alienate Duterte from his constituents at home, who have given him high approval marks amid a bloody crackdown on drugs that has earned international criticism.

The acquisition is expected to close on or about July 1, 2018, subject to regulatory approval from the New York Attorney General and certain closing conditions.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

But if the Facebook Like is protected speech because it ostensibly communicates «the user's approval... and support» of the person, status or thing liked, as Traxler wrote, then what of liking things sarcastically or in jest, or — to use an example from another social network — of «hate - favoriting» on Twitter?

According to a recent Reuters report, depending on who takes a Senate seat from several of these battle ground states and who wins certain gubernatorial races could mean which of the energy topics — EPA carbon regulations, the Keystone Pipeline XL's approval, relaxing crude oil export rules, developing clean energy technology — will take priority.

Adequate capital gives the franchisee time to learn on the job and recover from missteps, so every franchisor should take a conservative approach to franchisee approval in this area.

After all, «biotech» is a pretty broad category that encompasses everything from next - gen cancer therapy makers that are already on the market and racking up sales to firms that are still years away from even filing for their first FDA approval.

From the time Enbridge began talking publicly about Northern Gateway almost a decade ago, the oil pipeline project — which is expected to get federal cabinet approval any day now — got off on the wrong foot by the company's lack of a presence in British Columbia.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Its military projects would mean the acquisition is likely to be subject to regulatory approval from Committee on Foreign Investment in the United States.